Diagnostic value of fluorescence in situ hybridization assay in malignant mesothelioma: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4745-4749

  Wan, Chun ^a   Shen, Yong Chun ^a   Liu, Meng Qi ^b   Yang, Ting ^a   Wang, Tao ^a   Chen, Lei ^a   Yi, Qun ^a   Wen, Fu Qiang ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Fluorescence in situ hybridization; Malignant mesothelioma; Meta analysis

Indexed keywords

EID: 84874005450     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4745     Document Type: Article

References (31)

1. Allen TG (2005). Recognization of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies. Arch Pathol Lab Med, 129, 1415-20.
2. British Thoracic Society Standards of Care Committee (2007). BTS statement on malignant mesothelioma in the UK, 2007. Thorax, 62, ii1 - 19.
3. Chapman A, Mulrennan S, Ladd B, Muers MF (2008). Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax, 63, 435-9.
4. Chiosea S, Krasinskas A, Cagle PT, et al (2008). Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathol, 21, 742-7.
5. Chung CT, Santos Gda C, Hwang DM, et al (2010). FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol, 63, 630-4.
6. Dacic S, Kothmaier H, Land S, et al (2008). Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch, 453, 627-35.
7. Devillé WL, Buntinx F, Bouter LM, et al (2002). Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol, 2, 9.
8. Factor RE, Dal CP, Fletcher JA, Cibas ES (2009). Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma. Cancer, 117, 247-53.
9. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A (2010). Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer, 68, 39-43.
10. Glas AS, Lijmer JG, Prins MH, et al (2003). The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol, 56, 1129-35.
11. Husain AN, Colby TV, Ordóñez NG, et al (2009). Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med, 133, 1317-31.
12. Illei PB, Ladanyi M, Rusch VW, Zakowski MF (2003). The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer, 99, 51-6.
13. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM (2008). Cochrane Diagnostic Test Accuracy Working Group: Systematic reviews of diagnostic test accuracy. Ann Intern Med, 149, 889-97.
14. Lijmer JG, Bossuyt PM, Heisterkamp SH (2002). Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med, 21, 1525-37.
15. López-Ríos F, Chuai S, Flores R, (2006). Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res, 66, 2970-9.
16. Luo L, Shi HZ, Liang QL, et al (2010). Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Resp Med, 104, 149-56.
17. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, e1000097.
18. Monaco SE, Shuai Y, Bansal M, et al (2011). The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol, 135, 619-27.
19. Musti M, Kettunen E, Dragonieri S, et al (2006). Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogen, 170, 9-15.
20. Onofre FB, Onofre AS, Pomjanski N, et al (2008). 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer, 114, 204-15.
21. Pereira TC, Saad RS, Liu Y, Silverman JF (2006). The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol, 13, 174-84.
22. Robinson BW, Lake RA (2005). Advances in malignant mesothelioma. N Engl J Med, 353, 1591-603.
23. Savic S, Franco N, Grilli B, et al (2010): Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest, 138, 137-44.
24. Senyigit A, Bayram H, Babayigit C, et al (2000). Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT fi ndings in 117 patients. Respiration, 67, 615-22.
25. Shin HJ, Shin DM, Tarco E, Sneige N (2003). Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer, 99, 233-39.
26. Takeda M, Kasai T, Enomoto Y, et al (2010). 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int, 60, 395-99.
27. Takeda M, Kasai T, Enomoto Y, et al (2012). Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J Clin Pathol, 65, 77-82.
28. Tsuchiya KD (2011). Fluorescence in situ hybridization. Clin Lab Med, 31, 525-42.
29. Walter SD (2002). Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med, 21, 1237-56.
30. Whitaker D (2000). The cytology of malignant mesothelioma. Cytopathology, 11, 139-51.
31. Whiting P, Rutjes AW, Reitsma JB, et al (2003). The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 25.